A-shares closed · 港股休市 Quotes 行情 · 25 Sep 17:19 CST
26 Sep 2026 · 20:26 CST Terminal Access 终端入口 →
920478.BJ北京证券交易所 · 北交所 BSE

Heryi Pharma 峆一药业

Chemical Pharmaceuticals 化学制药
¥11.37−¥0.17 · −1.47%Delayed 行情延迟 · 24 Sep 2026 · 15:36 CST · CNY
Open 开盘
¥11.50
High 最高
¥12.01
Low 最低
¥11.18
Prev Close 昨收
¥11.54
Volume 成交量
959.5万股
Turnover 成交额
¥1.11亿
Mkt Cap 总市值
¥13亿
P/E 市盈率
173.8×
Recent Activity 近期动态All Filings 全部公告 →

One significant filing since 29 May 2026, on guarantee or financial assistance (28 Jul 2026): 关于为控股子公司提供担保的公告.
自 29 May 2026 起有一份重大公告(guarantee or financial assistance,28 Jul 2026):关于为控股子公司提供担保的公告。

Price History 价格走势

1 session 个交易日, Thu 24 Sep 2026 · Live one-minute prices · High 最高 ¥11.99 · Low 最低 ¥11.20 · −1.47% on the previous close of ¥11.54
11.2011.4011.6011.80
Volume 成交量
3,983
09:3010:3011:3014:0015:00
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
Measure 指标This Company 本公司Peer Median 同业中值Standing 排位
Market Cap 市值¥13亿¥63亿2nd lowest of 158 · 158 家中第 2 低
Trailing P/E 市盈率173.8x38.6x8th highest of 112 · 112 家中第 8 高
P/B 市净率2.5x2.5x76th lowest of 157 · 157 家中第 76 低
Revenue Growth 营收增速-53.3%1.6%2nd lowest of 156 · 156 家中第 2 低
Profit Growth 净利增速-106.3%1.9%11th lowest of 158 · 158 家中第 11 低
Gross Margin 毛利率29.2%50.2%34th lowest of 155 · 155 家中第 34 低
Net Margin 净利率-8.1%9.8%27th lowest of 157 · 157 家中第 27 低
Return on Equity 净资产收益率-0.5%3.1%32nd lowest of 157 · 157 家中第 32 低
Debt to Assets 资产负债率21.1%28.0%55th lowest of 158 · 158 家中第 55 低
Grade Score 评级得分21516th lowest of 157 · 157 家中第 6 低

Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间,158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业;无盈利的公司没有市盈率。

Largest Peers 主要同业
Peer 同业Market CapP/EP/BRevenue GrowthNet MarginROEGrade
Beone Medicines 百济神州¥3,979亿92.9x11.2x26.8%14.7%9.9%B
Hengrui Pharma 恒瑞医药¥2,977亿38.5x4.6x-1.9%28.9%8.0%C
Haisco Pharmaceutical Group 海思科¥699亿73.7x14.3x54.7%27.5%18.3%B
CSPC Innovation Pharmaceutical 石药创新¥620亿60.6x15.8x208.7%47.9%38.2%B
Sichuan Kelun Pharmaceutical 科伦药业¥618亿33.8x2.5x-2.7%16.1%4.6%C
Fosun Pharma 复星医药¥610亿18.0x1.3x4.8%10.5%3.5%D
Innocare 诺诚健华¥528亿57.5x6.9x55.5%21.1%3.2%C
Allist 艾力斯¥469亿17.5x5.5x39.9%46.4%19.7%B
Huadong Medicine 华东医药¥457亿13.2x1.8x1.8%8.3%7.3%C
Shenzhen Salubris Pharmaceuticals 信立泰¥337亿50.0x3.9x16.3%15.8%4.3%C
Humanwell Healthcare ST人福¥307亿15.1x1.6x-0.0%14.0%6.8%C
Apeloa Pharmaceutical 普洛药业¥293亿34.5x4.5x-11.4%10.8%8.1%D
Zelgen 泽璟制药¥288亿52.5x16.8x220.9%53.1%45.7%B
Dizal Pharmaceutical 迪哲医药¥263亿—23.2x47.2%-40.8%-17.2%D
Heryi Pharma 峆一药业¥13亿173.8x2.5x-53.3%-8.1%-0.5%E

Peers are listed by market cap, with this company highlighted. 同业按市值排列,本公司高亮显示。